Just processed by the SEC on this bright Friday afternoon: TraceLink, a nine-year-old software-as-a-service platform for tracking and tracing pharmaceuticals and trying to weed out counterfeit prescription drugs in the process, has raised $60 million in Series D funding. The filing shows that 18 firms participated, including, presumably, Goldman Sachs Growth Equity, which had led the company’s […]...